Printer Friendly

PROGENICS PHARMACEUTICALS NAMES FINANCE DIRECTOR

 PROGENICS PHARMACEUTICALS NAMES FINANCE DIRECTOR
 TARRYTOWN, N.Y., Sept. 11 /PRNewswire/ -- Progenics Pharmaceuticals,


Inc. today announced the appointment of Robert A. McKinney to the position of director of finance and administration. Mr. McKinney, a C.P.A., will be responsible for financial and administrative activities at Progenics. Mr. McKinney was previously corporate controller of VIMRx Pharmaceuticals Inc., a publicly traded pharmaceutical concern.
 "Rob brings extensive experience in management and finance to Progenics," said Mark F. Dalton, president of Tudor Investment Corp. and a director of Progenics. "He will play an integral role in the evolution of Progenics into a mature biotechnology company."
 Progenics also announced the appointment of Joel D. Sendek to the position of manager, corporate development and Patricia Fazio-Miceli to the position of manager, laboratory operations. Mr. Sendek worked previously in the corporate finance department at Goldman, Sachs & Co. in New York. Ms. Fazio-Miceli was senior research technician and laboratory manager at Howard Hughes Medical Institute of Columbia University, N.Y. Mr. McKinney, Mr. Sendek, and Ms. Fazio-Miceli will report to Paul J. Maddon, M.D., Ph.D., Progenics' chairman and CEO.
 "These appointments give Progenics a strong administrative team to complement the outstanding group of scientists we have already assembled," said Dr. Maddon.
 Progenics Pharmaceuticals, Inc., headquartered in Tarrytown, is a privately held biotechnology company specializing in the design and discovery of therapeutics and vaccines to treat human viral disease, particularly HIV infection.
 -0- 9/11/92
 /CONTACT: Joel D. Sendek, manager, corporate development of Progenics Pharmaceuticals, Inc., 914-789-2800, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, Inc., 212-979-9180, for Progenics Pharmaceuticals, Inc./ CO: Progenics Pharmaceuticals, Inc. ST: New York IN: MTC SU: PER


TS-OS -- NY011 -- 8361 09/11/92 09:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 11, 1992
Words:288
Previous Article:JOAN BAEZ SIGNS WITH VIRGIN RECORDS; NEW ALBUM, 'PLAY ME BACKWARDS,' SET FOR RELEASE OCT. 6
Next Article:FAX ASSOCIATION ANNOUNCES EDUCATIONAL SEMINARS
Topics:


Related Articles
NIH AWARDS SBIR GRANT TO PROGENICS PHARMACEUTICALS TO STUDY HIV LIFE CYCLE
PROGENICS PHARMACEUTICALS AND CENTERS FOR DISEASE CONTROL SIGN COLLABORATIVE AGREEMENT
PROGENICS PHARMACEUTICALS RAISES $5.1 MILLION IN PRIVATE PLACEMENT
PROGENICS PHARMACEUTICALS AWARDED NIH GRANT TO DEVELOP NEW HIV THERAPEUTICS AND CLINICAL ASSAYS
AMERICAN CYANAMID AND PROGENICS PHARMACEUTICALS SIGN RESEARCH AGREEMENT
PROGENICS PHARMACEUTICALS RAISES $3.6 MILLION IN PRIVATE PLACEMENT
PROGENICS PHARMACEUTICALS INITIATES CLINICAL TESTING OF HIV IMAGING AGENT PROSCAN-A
PROGENICS, SOUTHWEST FOUNDATION, AND UNIV. OF OKLAHOMA AWARDED U.S. ARMY CONTRACT TO DEVELOP NEW HIV VACCINE
PROGENICS PHARMACEUTICALS RAISES $7.0 MILLION IN PRIVATE PLACEMENT
Progenics Names Kurt Briner and Ronald Prentki to Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters